UroGen Pharma Ltd.
URGN · FY2025 · Fiscal year ended Dec 31, 2025 · 10-K filed Mar 2026
Open the dashboardInfographicSummary
FY2025 key figures
| $ | FY2025 | FY2024 | Change |
|---|---|---|---|
| Revenue | $110M | $90.4M | +21.4% |
| Operating income | −$125M | −$96.8M | −29.0% |
| Net income | −$153M | −$127M | −21.0% |
Latest quarter: Q3 2026
Form 10-Q · Three months ended Sep 30, 2026 · filed Nov 4, 2026
| $ | Q3 2026 | Year earlier | Change |
|---|---|---|---|
| Revenue | $89.0M | $27.5M | +224% |
| Operating income | $8.30M | −$27.4M | |
| Net income | −$1.50M | −$33.3M | +95.5% |
Q3 2026 dashboardQ3 2026 infographic
Questions
- What was UroGen's revenue in FY2025?
- $110M in FY2025 (Fiscal year ended Dec 31, 2025), +21.4% vs $90.4M a year earlier, per its 10-K filed Mar 2026.
- Was UroGen profitable in FY2025?
- No: net income was −$153M and operating income −$125M in FY2025.
- What was UroGen's revenue in Q3 2026?
- $89.0M (+224% vs a year earlier), per its Form 10-Q filed Nov 4, 2026.